Novel Strategies to Antagonize Cocaine-Enhanced HIV Pathobiology
对抗可卡因增强的艾滋病毒病理学的新策略
基本信息
- 批准号:8598406
- 负责人:
- 金额:$ 42.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-07-01 至 2018-03-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAdherenceAdhesionsAffectBehavioralBlood CirculationBypassCD4 Positive T LymphocytesCell CommunicationCellsCocaineCocaine UsersComplexCytoskeletal ProteinsCytoskeletonDendritic CellsDrug usageDrug userElementsEndosomesEndotheliumEpidemiologyExposure toFamilyFosteringFoundationsFunctional disorderGatekeepingGoalsHIVHIV InfectionsHIV-1High Endothelial VenuleHost DefenseHumanImmigrationImmuneImmune responseImmune systemIn VitroKnowledgeLaboratoriesLigandsLymphaticLymphatic EndotheliumLysosomesMediatingMethodologyMethodsModelingMolecularMusPathologyPathway interactionsPermeabilityPopulationProductionResearchRiskRisk BehaviorsRoleSatellite VirusesSignal PathwaySignal TransductionSynapsesSystemT-LymphocyteTherapeutic InterventionTranslatingVirusVirus ReplicationWorkcell typecofactorcytokinedesignin vitro Modelin vivoinnovationinsightlymph nodesmigrationmonolayermouse modelnovelnovel strategiespathogenpreventprotective effectprotein transportpublic health relevancereceptortherapeutic targettraffickingtransmission process
项目摘要
DESCRIPTION (provided by applicant): Cocaine is a prominent cofactor in the epidemiology of HIV, associated with risky behavior that increases exposure to virus and undermines adherence to treatment. But independent of behavioral factors, cocaine appears to increase HIV replication and accelerate progression to AIDS. We hypothesize this occurs because cocaine facilitates HIV subversion of key host defenses. How does HIV itself subvert immune defenses? One pathway involves dendritic cells (DCs) that normally capture pathogens and degrade them in lysosomes. HIV can bypass this pathway by complexing with DC-SIGN and cytoskeletal proteins, trafficking to endosomes rather than lysosomes, so it is not degraded. Endosome-associated virus is then richly presented by DCs to CD4+ T-cells via the immune synapse. HIV can also subvert an intact lymphatic endothelial (LE) barrier through altering novel Robo receptors which normally signal to stabilize the cytoskeleton. Robo dysregulation increases endothelial permeability, which would promote virus dissemination into the bloodstream. Similar HIV effects may occur in high endothelial venules (HEVs), the "gatekeepers" for immune cell trafficking in lymph nodes. Studies show cocaine can specifically alter cytoskeletal and signaling pathways in DCs and endothelium that would work to the benefit of HIV. The overall objective of this proposal is to gain a deeper understanding of how HIV and cocaine partner on a molecular level to subvert host defenses. We will model their effects both in vitro and in vivo in the BLT humanized mouse, and explore how targeting novel Robo receptors may oppose the deleterious changes triggered by cocaine that enhance HIV pathobiology. Our initial studies support this strategy: Robo signaling protected LE from HIV hyperpermeability and in DCs inhibited virus transmission to T-cells. Specific points of innovation include: (1) focus on alterations of the cytoskeletal apparatus as a unique way HIV and cocaine may disarm immune responses; (2) utilize purified populations of LEs and HEVs, whose roles in limiting HIV are not yet well characterized; (3) exploit the newly identified ligands and receptors of the Slit/Robo family in antagonizing cocaine-facilitated HIV subversion of immune defense; (4) apply cutting-edge methodology in the in vivo HIV-BLT mouse model to translate in vitro observations. The specific aims are: (1) further characterize molecular effects of HIV and cocaine in DCs that enhance virus transmission to T-cells; (2) characterize molecular changes in LE and HEV barriers due to HIV and cocaine, and further assess protective effects of Robo signaling; (3) model in vitro DC and T-cell interactions with LE and HEV in the presence of HIV and cocaine; (4) assess in vivo in the BLT humanized mouse how Robo signaling may antagonize cocaine-enhanced HIV pathobiology. By generating this new knowledge, we hope to provide the foundation for innovative strategies to prevent or contain HIV infection in users of cocaine.
描述(由申请人提供):可卡因是艾滋病毒流行病学的重要辅助因素,与增加病毒暴露和破坏治疗依从性的危险行为有关。但与行为因素无关,可卡因似乎增加了艾滋病毒的复制,加速了艾滋病的发展。我们假设发生这种情况是因为可卡因促进了HIV对关键宿主防御的颠覆。HIV本身是如何破坏免疫防御的?一种途径涉及树突状细胞(dc),树突状细胞通常捕获病原体并在溶酶体中降解它们。HIV可以通过与DC-SIGN和细胞骨架蛋白络合绕过这一途径,转运到核内体而不是溶酶体,因此它不会被降解。内核体相关病毒通过dc通过免疫突触大量呈递到CD4+ t细胞。HIV还可以通过改变新的Robo受体来破坏完整的淋巴内皮(LE)屏障,这些受体通常发出信号来稳定细胞骨架。机器人的失调会增加内皮细胞的渗透性,这会促进病毒传播到血液中。类似的HIV效应可能发生在高内皮小静脉(HEVs)中,它是免疫细胞在淋巴结运输的“看门人”。研究表明,可卡因可以特异性地改变dc和内皮细胞的细胞骨架和信号通路,这可能对HIV有益。本提案的总体目标是更深入地了解艾滋病毒和可卡因如何在分子水平上合作破坏宿主防御。我们将在BLT人源化小鼠体内和体外模拟它们的作用,并探索靶向新型Robo受体如何对抗可卡因引发的增强HIV病理生物学的有害变化。我们的初步研究支持这一策略:Robo信号保护LE免受HIV高渗透性,并且在dc中抑制病毒向t细胞的传播。具体的创新点包括:(1)专注于改变细胞骨架装置,作为艾滋病毒和可卡因可能解除免疫反应的独特方式;(2)利用纯化的LEs和hev群体,它们在限制HIV方面的作用尚未很好地表征;(3)利用新发现的Slit/Robo家族配体和受体拮抗可卡因介导的HIV对免疫防御的破坏;(4)在体内HIV-BLT小鼠模型中应用前沿方法翻译体外观察结果。具体目标是:(1)进一步表征艾滋病毒和可卡因在dc中的分子效应,增强病毒向t细胞的传播;(2)表征HIV和可卡因导致的LE和HEV屏障的分子变化,并进一步评估Robo信号的保护作用;(3)在HIV和可卡因存在的情况下,体外建立DC和t细胞与LE和HEV相互作用的模型;(4)在BLT人源化小鼠体内评估Robo信号如何拮抗可卡因增强的HIV病理生物学。通过产生这种新知识,我们希望为预防或控制可卡因使用者感染艾滋病毒的创新战略提供基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEROME E GROOPMAN其他文献
JEROME E GROOPMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEROME E GROOPMAN', 18)}}的其他基金
Cocaine induces production of infectious large extracellular vesicles (lEV) and regulates neuro-inflammation
可卡因诱导产生传染性大细胞外囊泡 (lEV) 并调节神经炎症
- 批准号:
10208847 - 财政年份:2020
- 资助金额:
$ 42.25万 - 项目类别:
Novel Mechanisms of Disarming Anti-HIV Host Defenses by Methamphetamine
甲基苯丙胺解除抗艾滋病毒宿主防御的新机制
- 批准号:
8900552 - 财政年份:2015
- 资助金额:
$ 42.25万 - 项目类别:
Novel Mechanisms of Disarming Anti-HIV Host Defenses by Methamphetamine
甲基苯丙胺解除抗艾滋病毒宿主防御的新机制
- 批准号:
9113553 - 财政年份:2015
- 资助金额:
$ 42.25万 - 项目类别:
Novel Strategies to Antagonize Cocaine-Enhanced HIV Pathobiology
对抗可卡因增强的艾滋病毒病理学的新策略
- 批准号:
8669962 - 财政年份:2013
- 资助金额:
$ 42.25万 - 项目类别:
Inhibition of HIV at the Immune Synapse Utilizing Novel Ligands and Receptors
利用新型配体和受体抑制免疫突触中的 HIV
- 批准号:
7932131 - 财政年份:2008
- 资助金额:
$ 42.25万 - 项目类别:
Inhibition of HIV at the Immune Synapse Utilizing Novel Ligands and Receptors
利用新型配体和受体抑制免疫突触中的 HIV
- 批准号:
7683286 - 财政年份:2008
- 资助金额:
$ 42.25万 - 项目类别:
Inhibition of HIV at the Immune Synapse Utilizing Novel Ligands and Receptors
利用新型配体和受体抑制免疫突触中的 HIV
- 批准号:
8116997 - 财政年份:2008
- 资助金额:
$ 42.25万 - 项目类别:
Inhibition of HIV at the Immune Synapse Utilizing Novel Ligands and Receptors
利用新型配体和受体抑制免疫突触中的 HIV
- 批准号:
8306236 - 财政年份:2008
- 资助金额:
$ 42.25万 - 项目类别:
Pathogenesis of Hepatic Injury with HCV/HIV Coinfection
HCV/HIV 合并感染肝损伤的发病机制
- 批准号:
6657216 - 财政年份:2001
- 资助金额:
$ 42.25万 - 项目类别:
Pathogenesis of Hepatic Injury with HCV/HIV Coinfection
HCV/HIV 合并感染肝损伤的发病机制
- 批准号:
6450551 - 财政年份:2001
- 资助金额:
$ 42.25万 - 项目类别:
相似海外基金
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 42.25万 - 项目类别:
Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 42.25万 - 项目类别:
Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 42.25万 - 项目类别:
Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 42.25万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 42.25万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 42.25万 - 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 42.25万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 42.25万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 42.25万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 42.25万 - 项目类别:
Fellowship Programs